伏格列波糖胶囊联合磷酸西格列汀片治疗老年性2型糖尿病的疗效观察

doi:10.3969/j.issn.1671-7171.2019.07.002

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the efficacy of voglibose capsule combined with sitagliptin phosphate tablets in the treatment of elderly patients with type 2 diabetes mellitus (T2DM). 【Methods】A total of 186 patients with T2DM admitted to our hospital from February 2016 to May 2018 were enrolled. Patients were divided into the observation group and the control group by the random number table method, with 93 cases in each group. The control group received oral sitagliptin phosphate tablets and the observation group received oral voglibose capsules and sitagliptin phosphate tablets. The levels of fasting blood glucose (FPG) and 2 hours postprandial blood glucose (2hPG) were measured by glucose oxidase method before and after treatment, and the levels of HbA1c were analyzed by high performance liquid chromatography. The average daily blood glucose fluctuation (MAGE) and blood glucose standard deviation (SD) were calculated according to the blood glucose map in the Accu-Chek Performa Roche blood glucose meter, and the incidence of hypoglycemia was recorded. The incidence of adverse reactions in the two groups during treatment was recorded. 【Results】 Before treatment, there were no significant differences in the levels of FPG, 2 h PG and HbA1c between the two groups (P>0.05). After treatment, the levels of FPG, 2 h PG and HbA1c were significantly lower in the two groups (P<0.05). The values in the observation group were remarkably lower than those in the control group (P<0.05). The incidence of daily mean MAGE, SD and hypoglycemia in the observation group were significantly lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group and the control group were 9.68% and 10.75%, respectively. There was no significant difference between the two groups (P>0.05). 【Conclusion】 Voglibose capsule combined with sitagliptin phosphate tablets in the treatment of T2DM is better than single sitagliptin phosphate tablets. It shows that the blood sugar fluctuation is smaller, the incidence of hypoglycemia is lower, and it is safe and reliable.

Key words： Diabetes Mellitus, Type 2/DT Drug Therapy, Combination Aged

Received: 26 September 2018

PACS:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Wei
	LUO Yong
	HE Yan

Cite this article:

XU Wei,LUO Yong,HE Yan. Therapeutic Effect of Voglibose Capsule Combined with Sitagliptin Phosphate Tablets in Elderly Patients with Type 2 Diabetes[J]. JOURNAL OF CLINICAL RESEARCH, 2019, 36(7): 1252-1254.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2019.07.002 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2019/V36/I7/1252

[1] 史春虹, 王璐, 白然,等. 西格列汀和伏格列波糖分别联合实时动态胰岛素泵对新诊断2型糖尿病患者的疗效对比[J].中华医学杂志, 2016, 96(32):2554-2558.
[2] 胡晓丽. 胰岛素泵( 门冬胰岛素) 联合西格列汀方案对T2DM的治疗效果分析[J].中国现代药物应用, 2016, 10(15):119-121.
[3] 邹峰. 西格列汀和二甲双胍复方制剂治疗新发2型糖尿病临床疗效和安全性分析[J].慢性病学杂志, 2017,16(2):220-222.
[4] 张茹. 磷酸西格列汀和伏格列波糖分别联合二甲双胍及短期胰岛素对于新诊断2型糖尿病临床疗效的随访研究[D].大连医科大学, 2016.
[5] 李英昭, 郭向阳, 尹洪涛,等. 西格列汀对需要大剂量胰岛素治疗的老年T2DM患者胰岛素抵抗及血糖波动的影响[J].重庆医学, 2017, 46(32):4492-4496.
[6] 郭荣梅. 阿卡波糖单用或联用磷酸西格列汀治疗新诊断老年T2DM的临床研究[J].长治医学院学报, 2017, 31(5):349-351.
[7] 贾敏. 胰岛素联合西格列汀治疗老年2型糖尿病的有效性和安全性[J].实用糖尿病杂志, 2017,16(5):23-24.
[8] 刘玉溥, 曾芳馨, 彭祖江,等. 西格列汀片联合地特胰岛素注射液治疗老年2型糖尿病的临床研究[J].中国临床药理学杂志, 2017, 33(15):1415-1417.
[9] 黄显丰, 李秀丽, 陶艳苹. 伏格列波糖胶囊联合精蛋白锌胰岛素治疗2型糖尿病相关性研究[J].中国老年保健医学, 2017, 15(2):41-42.
[10] Arao T, Okada Y, Torimoto K,et al. Comparison between effectiveness of 100 mg/day sitagliptin and a switch to mitiglinide calcium hydrate/voglibose from 50 mg/day sitagliptin in patients with Type 2 Diabetes [J].J UOEH,2017, 39(1):1-9.
[11] 程艳荣, 张麦浪, 王琳. 西格列汀联合胰岛素泵强化治疗门冬胰岛素30控制不佳T2DM患者的疗效观察[J].医学临床研究, 2016, 33(10):2009-2011.